| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Anaptysbio, Inc. (ANAB) has 13 insiders with recent SEC Form 4 filings, including 8 buys and 0 sells. ANAB is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 506.9K | $26.17M | - | |
| Other | 42.1K | $2.17M | - | |
| Dir | 39.7K | $2.05M | - | |
| CFO | 25.8K | $1.33M | - | |
| CFO | 21.9K | $1.13M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2017 | Topper James N88 | Director, 10% Owner | Buy | 400,000 | $15.00 | $6,000,000.00 | +42.4% | |
| Jan 31, 2017 | Frazier Healthcare Vii, L.P. | 10% Owner | Buy | 400,000 | $15.00 | $6,000,000.00 | New | |
| Jan 31, 2017 | Novo A/s58 | 10% Owner | Buy | 50,000 | $15.00 | $750,000.00 | +1.7% | |
| Jan 31, 2017 | Frazier Healthcare V, LP | 10% Owner | Buy | 400,000 | $15.00 | $6,000,000.00 | New | |
| Jan 31, 2017 | Lydon Nicholas | Director | Buy | 16,666 | $15.00 | $249,990.00 | +6.2% |